-
Vascular Health and Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Editorial: Metabolic syndrome: sign of things to come ||FREE PAPER||
(2085) Views (410) Full article downloads
Author: Reza Tabrizchi
Published Date May 2006
Volume 2006:2(3) Pages 193 - 194
DOI: http://dx.doi.org/10.2147/VHRM.S
Reza Tabrizchi
Division of Basic Medical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St John’s, NL, Canada
In a recent article in Vascular Health and Risk Management, Paoletti and colleagues (2006) pointed out that individuals with metabolic syndrome (MS) have twice the risk of dying and three times higher risk of having heart attacks or stroke compared with individuals without this syndrome. Moreover, people with MS have a five-fold greater risk of developing type-2 diabetes. Thus MS could become a leading cause of morbidity/mortality in the world population (Paoletti et al 2006). In the current issue of Vascular Health and Risk Management, Mathieu and colleagues (2006) have proposed a link between MS and atherosclerosis suggesting that individual with the syndrome have a substantially higher risk of coronary heart disease (CHD).
- Join ISVH
Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- The western diet and lifestyle and diseases of civilization
- Stiffness of the large arteries in individuals with and without Down syndrome
- Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study
- Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review




